Safeskin Income Up 145% In 4th Quarter On Lower Asian Manufacturing Costs
This article was originally published in The Gray Sheet
Safeskin sales of disposable latex and synthetic gloves soared 26% to $50 mil. in the fourth quarter of 1997 as earnings increased 145% to $12 mil. with the help of lower manufacturing costs in Asia, the firm reported Feb. 18.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.